Incidence and risk of endocrine and metabolic abnormalities linked to PARP inhibitors in solid tumors: a meta-analysis.

ABSTRACT:

Background

Poly (ADP-ribose) polymerase inhibitors (PARPi) serve as crucial therapeutic agents in solid tumor treatment. Preclinical investigations suggest a potential protective function of PARPi against endocrine and metabolic impairments. Nevertheless, the existing body of evidence remains inconclusive on this aspect.

Purpose

Our aim was to evaluate the potential impact of PARPi on endocrine and metabolic disruptions in clinical trials.

Data sources

We conducted a comprehensive search across the Medline, EMBASE, PubMed, and Web of Science databases, along with the ClinicalTrials.gov registry.

Study selection

Phase II/III randomized controlled trials (RCTs) investigating the effects of PARPi in metabolic and endocrine processes were selected for inclusion in

SUBMITTER: Fu S 

PROVIDER: S-EPMC11783722 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature